Core Viewpoint - Corning Jereh Pharmaceutical-B (09966) has seen a significant stock price increase of 14.03%, reaching HKD 10.81, with a trading volume of HKD 73.86 million, ahead of its upcoming board meeting to approve mid-term results [1] Financial Performance - The company expects to report a profit of no less than RMB 20 million for the first half of the year, a turnaround from a loss of approximately RMB 44.9 million in the same period last year [1] Business Developments - The turnaround to profitability is attributed to milestone revenues from three authorized collaborations and sales revenue from commercialized products [1] - The company’s self-developed PD-L1/integrin αvβ6 bispecific antibody-drug conjugate (ADC) JSKN022 has had its new drug clinical trial application formally accepted by the Center for Drug Evaluation of the National Medical Products Administration of China [1] - The company plans to initiate the first human clinical study of JSKN022 for the treatment of advanced malignant solid tumors, with no currently marketed ADCs targeting integrin αvβ6 or PD-L1 globally, and related investigational drugs are still in clinical research stages [1]
港股异动 | 康宁杰瑞制药-B(09966)涨幅扩大逾15% 下周四将发中期业绩 预计扭亏为盈至不少于2000万元